Our results from previously published predictive gene signatures generated in immune hot tumors such as melanoma, lung and urothelial cancers indicate that IL2RB has a strong association with the biology that underpins response to immune-checkpoint therapy and could be extrapolated to immune ‘hot’ MSI-H CRC tumors. Here, IL2RB is linked to melanoma.